Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation

被引:31
|
作者
Taha, Maie S. [1 ,2 ,3 ]
Padmakumar, Smrithi [1 ]
Singh, Amit [4 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 360 Huntington Ave, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Eye & Ear Infirmary, 243 Charles St, Boston, MA 02114 USA
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[4] Puretech Hlth, 6 Tide St, Boston, MA 02210 USA
关键词
Nanomedicine; Clinical translation; Drug delivery; Challenges; Nanoparticles; Quality attributes; Quality-by-design (QbD); NANOPARTICLE SURFACE-CHARGE; DRUG-DELIVERY SYSTEMS; PROTEIN CORONA; POLYMERIC NANOPARTICLES; DESIGN APPROACH; HYBRID NANOPARTICLES; LIPID NANOPARTICLES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; INORGANIC NANOPARTICLES;
D O I
10.1007/s13346-020-00744-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Nanomedicine is a rapidly emerging field with several breakthroughs in the therapeutic drug delivery application. The unique properties of the nanoscale delivery systems offer huge advantages to their payload such as solubilization, increased bioavailability, and improved pharmacokinetics with an overall goal of enhanced therapeutic index. Nanomedicine has the potential for integrating and enabling new therapeutic modalities. Several nanoparticle-based drug delivery systems have been granted approval for clinical use based on their outstanding clinical outcomes. Nanomedicine faces several challenges that hinder the realization of its full potential. In this review, we discuss the critical formulation- and biological-related quality features that significantly influence the performance of nanoparticulate systems in vivo. We also discuss the quality-by-design approach in the pharmaceutical manufacturing and its implementation in the nanomedicine. A deep understanding of these nanomedicine quality checkpoints and a systematic design that takes them into consideration will hopefully expedite the clinical translation process. Graphical abstract
引用
收藏
页码:766 / 790
页数:25
相关论文
共 50 条
  • [21] The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs
    Saitoh, Satoshi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (12): : 1475 - 1481
  • [22] Current understandings and clinical translation of nanomedicines for breast cancer therapy
    Jiang, Yike
    Jiang, Ziyi
    Wang, Mingzhe
    Ma, Lan
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 180
  • [23] Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
    Dri, Diego Alejandro
    Gaucci, Elisa
    Torrieri, Ilaria
    Carafa, Maria
    Marianecci, Carlotta
    Gramaglia, Donatella
    PHARMACEUTICS, 2022, 14 (07)
  • [24] Current approaches of nanomedicines in the market and various stage of clinical translation
    Xiaoting Shan
    Xiang Gong
    Jie Li
    Jingyuan Wen
    Yaping Li
    Zhiwen Zhang
    Acta Pharmaceutica Sinica B, 2022, 12 (07) : 3028 - 3048
  • [25] Current approaches of nanomedicines in the market and various stage of clinical translation
    Shan, Xiaoting
    Gong, Xiang
    Li, Jie
    Wen, Jingyuan
    Li, Yaping
    Zhang, Zhiwen
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (07) : 3028 - 3048
  • [26] Preclinical Evaluation and Clinical Translation of Magnetite-Based Nanomedicines
    Nuzhina, Julia, V
    Shtil, Alexander A.
    Prilepskii, Artur Y.
    Vinogradov, Vladimir V.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2019, 54
  • [27] Outlining critical quality attributes (CQAs) as guidance for the development of orodispersible films
    Borges, Ana Filipa
    Silva, Claudia
    Coelho, Jorge F. J.
    Simoes, Sergio
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2017, 22 (02) : 237 - 245
  • [28] Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
    Dri, Diego Alejandro
    Marianecci, Carlotta
    Carafa, Maria
    Gaucci, Elisa
    Gramaglia, Donatella
    PHARMACEUTICS, 2021, 13 (03)
  • [29] Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
    Kamaly, Nazila
    Xiao, Zeyu
    Valencia, Pedro M.
    Radovic-Moreno, Aleksandar F.
    Farokhzad, Omid C.
    CHEMICAL SOCIETY REVIEWS, 2012, 41 (07) : 2971 - 3010
  • [30] Characterization of critical quality attributes of self-amplifying mRNA: A novel vaccine/therapeutic modality
    Xie, Mandy
    Maruggi, Giulietta
    Yu, Dong
    Moniotte, Nicolas
    Aggarwal, Kunal
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257